Skip to main content
ENSC
NASDAQ Life Sciences

Ensysce Sets Dec 14 Vote on 358.3M-Share Series C Conversion, Reverse Split and Share Increase

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.387
Mkt Cap
$7.534M
52W Low
$0.23
52W High
$2.17
52W Position info
68% above low
Off High info
82% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

ENSC sits 68% above its 52-week low of $0.23.

Summary

Ensysce's definitive proxy sets a December 14, 2026 meeting to vote on converting Series C Preferred into about 358.3 million shares, a 1-for-10 to 1-for-30 reverse split, and raising authorized shares to 500 million.


Key Events · Corporate Governance and Compliance · ENSC

  • Series C Conversion Vote Set

    Proposal 1 seeks approval to issue 358,292,000 common shares underlying Series C Preferred; post-conversion shares outstanding would rise from 19,456,794 to 377,748,794.

  • Reverse Split Proposed

    Proposal 2 authorizes a 1-for-10 to 1-for-30 reverse split, with the Board targeting a post-split price of roughly $7.00-$11.00 to meet Nasdaq's $4.00 initial listing bid requirement.

  • Authorized Shares to Double

    Proposal 3 would raise authorized common stock from 250,000,000 to 500,000,000 shares, contingent on the reverse split being implemented.

  • Delisting Risk on Non-Approval

    The proxy states that if Proposal 1 fails, the company cannot convert the Series C Preferred without facing Nasdaq delisting, and must re-solicit approval every six months.


Analysis · ENSC · Life Sciences

This definitive proxy locks in the December 14, 2026 annual meeting and puts the full post-merger capital structure to a shareholder vote. The central item is Proposal 1: approving conversion of Series C Preferred into roughly 358.3 million common shares, which would take shares outstanding from 19,456,794 to 377,748,794 — the new Cy Biopharma holders and PIPE investors would control the company. Because Nasdaq has deemed the deal a change of control, the company must first satisfy Nasdaq's $4.00 initial listing bid price, so Proposal 2 authorizes a reverse split of 1-for-10 to 1-for-30 (Board targeting roughly $7-$11 post-split) and Proposal 3 doubles authorized shares to 500 million. Failure to pass Proposal 1 risks delisting. The Board may adjourn the meeting (Proposal 9) to implement the split and secure Nasdaq listing approval before the remaining votes.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ENSC was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $0.23 to $2.17. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ENSC - Latest Insights

ENSC
Nov 04, 2026, 12:46 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.3719
Real-time Price: $0.3871 info
Change: +$0.0152 (+4%) info
Market Cap: $7.534M info
ENSC
Oct 30, 2026, 5:28 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.4313
Real-time Price: $0.3871 info
Change: -$0.0442 (-10%) info
Market Cap: $7.534M info
ENSC
Oct 23, 2026, 4:30 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $0.4847
Real-time Price: $0.3871 info
Change: -$0.0976 (-20%) info
Market Cap: $7.534M info
ENSC
Oct 15, 2026, 9:56 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $0.565
Real-time Price: $0.3871 info
Change: -$0.1779 (-31%) info
Market Cap: $7.534M info
ENSC
Aug 25, 2026, 5:12 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3905
Real-time Price: $0.3871 info
Change: -$0.0034 (-0.87%) info
Market Cap: $7.534M info